US2009215737A1PendingUtilityA1

Pharmaceutical Compositions - 2

Assignee: AHLEM CLARENCE NATHANIELPriority: Mar 23, 1999Filed: Oct 19, 2006Published: Aug 27, 2009
Est. expiryMar 23, 2019(expired)· nominal 20-yr term from priority
A61K 9/0031C07J 1/0011A61K 9/0019A61P 37/00A61K 31/56A61K 31/565A61K 31/568A61P 31/04A61K 9/127A61P 37/02C07J 1/00A61K 31/5685C07J 3/005Y02A50/30
71
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16α-bromo-3β-hydroxy-5α-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

Claims

exact text as granted — not AI-modified
1 - 12 . (canceled) 
     
     
         13 : A method to treat or ameliorate a  Mycobacterium  infection in a mammal, comprising administration of an effective amount of a compound to the mammal wherein the mammal is a human and the compound is 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate or 16α-bromo-3β-hydroxy-5α-androstan-17-one. 
     
     
         14 : The method of  claim 13  wherein the  Mycobacterium  infection is a  Mycobacterium tuberculosis  infection. 
     
     
         15 : The method of  claim 14  wherein the administration is by intermittent dosing. 
     
     
         16 . The method of  claim 14  wherein the compound is 16α-bromo-3β-hydroxy-5α-androstan-17-one. 
     
     
         17 : The method of  claim 16  wherein the human has an HIV infection. 
     
     
         18 : The method of  claim 14  wherein the compound is 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate. 
     
     
         19 : The method of  claim 18  wherein the human has an HIV infection.

Join the waitlist — get patent alerts

Track US2009215737A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.